36,897 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Acquired by Corient Private Wealth LLC

Corient Private Wealth LLC purchased a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 36,897 shares of the company’s stock, valued at approximately $98,000. Corient Private Wealth LLC owned approximately 0.13% of Aerovate Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Ieq Capital LLC bought a new position in Aerovate Therapeutics in the 4th quarter worth approximately $38,000. Barclays PLC increased its stake in shares of Aerovate Therapeutics by 310.8% in the 3rd quarter. Barclays PLC now owns 18,972 shares of the company’s stock valued at $39,000 after buying an additional 14,354 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Aerovate Therapeutics during the fourth quarter worth $198,000. FMR LLC raised its position in shares of Aerovate Therapeutics by 54,095.4% during the third quarter. FMR LLC now owns 82,919 shares of the company’s stock worth $173,000 after acquiring an additional 82,766 shares during the last quarter. Finally, Deltec Asset Management LLC acquired a new position in shares of Aerovate Therapeutics during the fourth quarter valued at $514,000.

Aerovate Therapeutics Stock Up 0.4 %

Shares of AVTE stock opened at $2.52 on Thursday. The firm has a market cap of $73.04 million, a price-to-earnings ratio of -0.84 and a beta of 1.01. Aerovate Therapeutics, Inc. has a 12 month low of $1.25 and a 12 month high of $30.29. The stock has a 50-day moving average price of $2.49 and a 200 day moving average price of $2.45.

Aerovate Therapeutics (NASDAQ:AVTE) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). Sell-side analysts predict that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.